Coherus BioSciences

We look forward to sharing the final data from our Phase 2 combination study of casdozo with standard of care in patients with liver cancer with the medical community at the upcoming 2025 ASCO-GI annual meeting. Casdozo has shown encouraging responses in the first line setting when added to the existing standard of care, atezolizumab and bevacizumab, and we’re excited to build upon these data with a new Phase 2 study evaluating casdozo in combination with toripalimab and bevacizumab. Read more about our upcoming presentation and our new Phase 2 study in patients with HCC: https://bit.ly/3ZHSnST

Yesterday we announced that we’ve entered into an agreement to divest the UDENYCA franchise to Intas Pharmaceuticals for up to $558M. Read the press release: https://bit.ly/3OBmUwu Please see important information here: https://bit.ly/3ZijLGF

Yesterday we announced that we’ve entered into an agreement to divest the UDENYCA franchise to Intas Pharmaceuticals for up to $558M. Read the press release: https://bit.ly/3OBmUwu Please see important information here: https://bit.ly/3ZijLGF

Today, we announced our attendance at the upcoming Citi Global Healthcare Conference. Theresa LaVallee, CDO, will also be taking part in the Novel Mechanisms in Oncology Panel moderated by Yigal Nochomovitz, Ph.D. on December 3rd. Head to our website or read today’s press release for full presentation information: https://bit.ly/4970I6N

Theresa LaVallee, Coherus's Chief Development Officer, joined Joni L Rutter, Laurence Sperling, and peter stein to discuss the Future of R&D in drug development in a panel moderated by Fierce Pharma editor Conor Hale at the Milken Institute 2024 Future of Health Summit. Listen to the discussion here: https://lnkd.in/e2s78cTn #MIHealthSummit

Today, we’re honoring all those who have served our country. Thank you for your bravery. #VeteransDay 

Don’t miss our presentation today at SITC 2024 on CHS-114, an anti-CCR8 cytolytic monoclonal antibody that preferentially depletes intratumoral Tregs and induces antitumor immune responses. View our poster https://bit.ly/3YaEEEg #oncology #CCR8

Attending SITC 2024? Stop by our presentation today to learn more about Casdozokitug, a first-in-class, anti-IL27 antagonistic antibody treatment and its potential to promote NK and T cell driven antitumor response in a Phase I study in patients with advanced solid tumors. View the poster: https://bit.ly/3XUGZSH #oncology

Join us for our Q3 2024 earnings call today, starting at 5:00 pm ET, to hear about our Q3 financial results and recent business highlights. Press release: https://bit.ly/3ChZ465 Listen to the webcast: https://bit.ly/4e9J1UU

Coherus will report Q3 2024 financial results on November 6, 2024. Starting at 5 pm EDT, CEO Denny Lanfear and the executive team will host a conference call and webcast to discuss Q3 2024 financial results and recent business highlights. Webcast link: https://bit.ly/4e9J1UU